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Abstract
 
Phenotypic markers, localization, functional activities, and mechanisms of action in vitro of
CD4
 
 
 
CD25
 
 
 
 T cells, purified from postnatal human thymuses, were investigated. These cells
showed poor or no proliferation in mixed lymphocyte culture (MLC), and suppressed in a
dose-dependent fashion the proliferative response to allogeneic stimulation of CD4
 
 
 
CD25
 
 
 
thymocytes. Virtually all CD4
 
 
 
CD25
 
 
 
 thymocytes constitutively expressed cytoplasmic T
lymphocyte antigen (CTLA)-4, surface tumor necrosis factor type 2 receptor (TNFR2), and
CCR8. They prevalently localized to perivascular areas of fibrous septa and responded to the
chemoattractant activity of CCL1/I-309, which was found to be produced by either thy-
mic medullary macrophages or fibrous septa epithelial cells. After polyclonal activation,
CD4
 
 
 
CD25
 
 
 
 
 
thymocytes did not produce the cytokines interleukin (IL)-2, IL-4, IL-5, IL-13,
interferon 
 
 
 
, and only a very few produced IL-10, but all they expressed on their surface
CTLA-4 and the majority of them also transforming growth factor (TGF)-
 
 
 
1. The suppressive
activity of these cells was contact dependent and associated with the lack of IL-2 receptor
(IL-2R) 
 
 
 
-chain (CD25) expression in target cells. Such a suppressive activity was partially in-
hibited by either anti–CTLA-4 or anti–TGF-
 
 
 
1, and was completely blocked by a mixture of
these monoclonal antibodies, which were also able to restore in target T cells the expression of
IL-2R 
 
 
 
-chain and, therefore, their responsiveness to IL-2. These data demonstrate that
CD4
 
 
 
CD25
 
 
 
 human thymocytes represent a population of regulatory cells that migrate in re-
sponse to the chemokine CCL1/I-309 and exert their suppressive function via the inhibition
of IL-2R 
 
 
 
-chain in target T cells, induced by the combined activity of CTLA-4 and mem-
brane TGF-
 
 
 
1.
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Introduction
 
Spontaneously occurring populations of T cells that regu-
late autoimmune reactions have been detected in animals
(1, 2). One such population is the CD4
 
 
 
CD25
 
 
 
 subset
found in normal mice (3). Neonatally thymectomized
mice, which are deficient in this population of T cells de-
velop multiorgan autoimmune disease, and the adoptive
transfer of CD4
 
 
 
CD25
 
 
 
 cells from normal mice can pro-
tect these animals from autoimmune diseases (4–6). The
existence of CD4
 
 
 
CD25
 
 
 
 regulatory T (Treg)
 
*
 
 cells has
recently been reported also in human peripheral blood (PB)
(7–14) and thymus (13). However, the phenotypic features
of CD4
 
 
 
CD25
 
 
 
 human Treg cells so far described are con-
troversial. In addition, the mechanism by which these cells
exert their suppressive activity is unclear. This is at least in
part due to the fact that human PB CD4
 
 
 
CD25
 
 
 
 T cells
represent a heterogeneous population containing not only
regulatory, but also activated IL-2 receptor (IL-2R)
 
 
 
-chain
(CD25)-expressing effector, T cells (14).
In this study, we have assessed phenotypic markers, lo-
calization, and functional activity of CD4
 
 
 
CD25
 
 
 
 T cells
purified from postnatal human thymuses. The results pro-
vide evidence that CD4
 
 
 
CD25
 
 
 
 human thymocytes ex-
hibit well recognizable phenotypic and functional features.
These cells showed indeed poor or no proliferation in
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CD4
 
 
 
CD25
 
 
 
 Regulatory Human Thymocytes
 
mixed lymphocyte culture (MLC) and suppressed in a
dose-dependent fashion the proliferative response to allo-
geneic stimulation of CD4
 
 
 
CD25
 
  
 
T cells. CD4
 
 
 
CD25
 
 
 
thymocytes constitutively expressed CTLA-4 in their cyto-
plasm, as well as TNF type 2 receptor (TNFR2), and
CCR8 on their surface membrane. These cells prevalently
localized to fibrous septa and the medulla of human thy-
mus, and responded to the chemoattractant activity of
CCL1/I-309, which was found to be produced by either
macrophages or epithelial cells present in the same areas.
After polyclonal activation, CD4
 
 
 
CD25
 
 
 
 thymocytes did
not produce IL-2, IL-4, IL-5, IL-13, IFN-
 
 
 
, and only a
few produced IL-10, but virtually all they expressed on
their surface CTLA-4 and the majority of them also ex-
pressed membrane TGF (mTGF)-
 
 
 
1. Finally, the suppres-
sive activity of these cells was contact dependent, and ap-
peared to be related to their ability to inhibit the expression
of IL-2R 
 
 
 
 chain in target T cells. Such a suppressive activ-
ity was partially inhibited by neutralizing mAbs against ei-
ther CTLA-4 or TGF-
 
 
 
1, and was completely blocked by
a mixture of these mAbs, which were also able to restore
the expression of IL-2R 
 
 
 
-chain in target T cells and,
therefore, their responsiveness to IL-2. These data strongly
suggest that the regulatory activity of CD4
 
 
 
CD25
 
 
 
 human
thymocytes is mediated by the combined action of CTLA-4
and TGF-
 
 
 
1 which are expressed on their surface mem-
brane after activation, via the inhibition of IL-2R 
 
 
 
-chain
expression in target T lymphocytes.
 
Materials and Methods
 
Reagents and Abs.
 
The medium used throughout was RPMI
1640 (Seromed), supplemented with 2 mM 
 
L
 
-glutamine, 1%
nonessential aminoacids, 1% pyruvate, 2 
 
 
 
 10
 
 
 
5
 
 M 2-ME (all
from GIBCO BRL). Unconjugated and FITC-, PE-, allophyco-
cyanin-, or peridin chlorophyll protein–conjugated anti-CD3
(SK7, mouse IgG1), anti-CD3 (UCHT1, mouse IgG1 used for
cell stimulation and immunohistochemistry stainings), anti-CD4
(SK3, mouse IgG1), anti-CD8 (SK1, mouse IgG1), anti-CD11c
(S-HCL-3, mouse IgG2b), anti-CD14 (M
 
 
 
9, mouse IgG2b),
anti-CD16 (3G8, mouse IgG1), anti-CD19 (4G7, mouse IgG1),
anti-CD25 (2A3, mouse IgG1), anti-CD28 (CD28.2, mouse
IgG1 used for cell stimulation), anti-CD34 (My10, mouse IgG1),
anti-CD56 (My31, mouse IgG1), anti-CD69 (L78, mouse IgG1),
anti-CD83 (HB15e, mouse IgG1), anti–TCR-
 
  
 
 (11F2, mouse
IgG1), anti–CTLA-4 (BNI3, mouse IgG2a used for flow cytom-
etry and cell cultures), anti-CCR4 (1G1, mouse IgG1), anti–IL-2
(5344.111, mouse IgG1), anti–IL-4 (3010.211, mouse IgG1),
anti–IL-5 (TRFK5, rat IgG1), anti–IL-10 (JES3–9D7, rat IgG1),
anti–IL-13 (JES10–5A2, rat IgG1), and anti–IFN-
 
 
 
 (4S.B3,
mouse IgG1) mAbs were purchased from Becton Dickinson. The
anti-glycophorin A and B (E3, mouse IgG1), and the anti-cyto-
keratin (C-11, mouse IgG1) mAbs were from Sigma-Aldrich.
 The anti-CD68 (KP1, mouse IgG1) mAb used for immuno-
histochemistry was from Dako. The PE-conjugated anti-TNFR2
(22235.311, mouse IgG2a), the purified anti–TGF-
 
 
 
1 (9016.2,
mouse IgG1) neutralizing mAb, TGF-
 
 
 
R2 (goat IgG) neutraliz-
ing Ab, and biotin-conjugated anti–TGF-
 
 
 
1 (chicken IgY) and
anti-LAP (TGF-
 
 
 
1) (goat IgG) Abs were purchased from R&D
Systems. All conjugated and unconjugated isotype-matched con-
trol Abs were purchased from Southern Biotechnology Associ-
ates, Inc., (mouse IgG1: clone 15H6; mouse IgG2a: clone
HOPC-1; mouse IgG2b: clone A-1, rat IgG, goat IgG, and rabbit
IgG). Human recombinant IL-2 was gifted by Eurocetus (Milan,
Italy). IL-15, CCL1/I-309, and CCL22/MDC human recombi-
nant cytokine and chemokines were from R&D Systems. The
anti-CCR8 rabbit polyclonal Ab used for flow cytometry was
from AMS Biotechnology. The anti-CCR8 (second extracellular
domain) goat polyclonal Ab used for immunohistochemistry was
from Alexis Biotechnology. The anti–I-309 rabbit polyclonal Ab
used for immunohistochemistry was from PeproTech. The goat
anti–mouse IgG and anti-CD25 Abs conjugated with magnetic
beads were obtained from Miltenyi Biotec. The CFSE was from
Molecular Probes.
 
Human Thymuses.
 
Normal postnatal thymus specimens were
obtained from 15 children, aged between 5 d and 3 yr, who un-
derwent corrective cardiac surgery at the Apuano Pediatric Hos-
pital of Massa Carrara, Italy. The procedures followed in the
study were in accordance with the ethical standards of the Re-
gional Committee on Human Experimentation.
 
Flow Cytometry Analysis.
 
Flow cytometry analysis on thymic
cell suspensions was performed as described previously (15, 16).
To assess the expression of cytoplasmic CTLA-4, cells were
washed twice with PBS, pH 7.2, fixed 15 min with formaldehyde
(2% in PBS, pH 7.2), washed twice with 0.5% BSA in PBS, pH
7.2, permeabilized with PBS, pH 7.2, containing 0.5% BSA and
0.5% saponin, and then incubated for 15 min at room tempera-
ture with the specific mAbs. Cells were then washed and ana-
lyzed on a BD-LSR cytofluorimeter using the CELLQuest™
software (Becton Dickinson). The area of positivity was deter-
mined using an isotype-matched mAb, a total of 10
 
4
 
 events for
each sample were acquired.
 
Isolation of CD4
 
 
 
CD25
 
 
 
 Thymocytes.
 
Negative selection of
CD4
 
 
 
 single-positive (SP) thymocytes was first performed by
high-gradient magnetic cell sorting, as described previously (15).
In brief, thymic MNC suspensions were incubated for 20 min
with anti-CD8, anti-CD14, anti-CD16, anti-CD19, anti-CD34,
anti-CD56, anti–TCR-
 
  
 
, anti-glycophorin A and B mAbs, ex-
tensively washed, and then incubated for additional 20 min with
goat anti–mouse polyclonal Ab conjugated to colloidal super-
paramagnetic microbeads, according to the MACS
 
®
 
 system
(Miltenyi Biotec). After washing, cells were separated on a CS
 
 
 
column. The remaining SP CD4
 
 
 
 T cells were then separated
into CD25
 
 
 
 or CD25
 
  
 
by positive selection by the use of anti-
CD25 MACS
 
® 
 
microbeads. The positive selections were per-
formed on LS
 
 
 
 columns. According to manufacturer’s instruc-
tions, positively selected cells were used in all the experiments
without removing the microbeads conjugated Ab. To exclude
possible artifacts, related to the presence in culture of microbeads
used for positive selection of CD4
 
 
 
CD25
 
 
 
 thymocytes, these
cells were also isolated by FACS
 
®
 
 sorting (FACSVantage™) by
using a PE-coupled anti-CD25 mAb and the responsiveness of
the two populations was compared.
 
Immunohistochemistry.
 
Immunohistochemical staining of thy-
mic sections with 5 
 
 
 
g/ml anti-CD3, 10 
 
 
 
g/ml anti-CD4, 10
 
 
 
g/ml anti-CD11c, 10 
 
 
 
g/ml anti-CD25, 5 
 
 
 
g/ml anti-CD68,
6 
 
 
 
g/ml anti-CD83, anti-cytokeratin (1:1,000 dilution) mAb, 2
 
 
 
g/ml anti-I-309 or 5 
 
 
 
g/ml anti-CCR8 rabbit polyclonal Ab,
was performed as detailed in previous papers (15, 16). Double
immunostaining was performed by using the avidin-biotin-per-
oxidase system with two different substrates, as described previ-
ously (15, 16). To identify on the same specimen two different
proteins, the 3-amino-9-ethyl-carbazole (AEC) (red color) and 
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the Vector SG (bluish gray) substrates were used, respectively
(15, 16).
 
Chemotactic Assay.
 
The chemotactic assay was performed ac-
cording to the technique described previously (15, 16). In brief,
CCL1/I-309 or CCL22/MDC were added at optimal concentra-
tions (100 nM) in RPMI 1640 containing 0.5% BSA to the bot-
tom well of a transwell chamber (3-
 
 
 
m pore size, 12 wells; Co-
star). 2 
 
 
 
 10
 
6
 
 freshly isolated CD4
 
 
 
CD25
 
 
 
 or CD4
 
 
 
CD25
 
 
 
thymocytes were resuspended in the same buffer and loaded into
the top well. Cell migration was allowed to occur for 4 h at 37
 
 
 
C
and cells migrating to the lower chamber were harvested and
counted by BD-LSR cytofluorimeter. Cells that migrated in the
presence of medium alone served as a negative control.
 
Labeling of CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
  
 
Thymocytes with
CFSE.
 
Labeling of CD4
 
 
 
CD25
 
 
 
 and CD4 CD25   thy-
mocytes with CFSE was performed as described previously (17).
In brief, cells were extensively washed and resuspended at final
concentration of 107 cells per milliliter in PBS. CFSE was added
at a final concentration of 5  M and incubated for 4 min at room
temperature. The reaction was stopped by cell washing with
RPMI 1640, containing 10% heat inactivated FCS.
Polyclonal Stimulation of CFSE-labeled CD4 CD25  and
CD4 CD25  Thymocytes. CD4 CD25  and CD4 CD25  pu-
rified thymocytes, after labeling with CFSE, were stimulated in
RPMI 1640 medium containing 10% FCS serum on plates
coated with anti-CD3 (5  g/ml) plus soluble anti-CD28 (10  g/
ml) mAbs. The cells were monitored every 2 d for CTLA-4,
TGF- 1 expression, and CFSE content and stimulated at day 6
for cytokine production.
Cytometric Analysis of Intracellular Cytokines Versus Prolifera-
tion. Intracytofluorymetric analysis of IL-2, IL-4, IL-5, IL-10,
IL-13, and IFN-  synthesis at single cell level was performed as
described previously (18), the only difference being stimulation
of cells already labeled with CFSE. In brief, 106 cells were stimu-
lated with 10 ng/ml PMA plus 1  M ionomycin for 6 h, the last
two of which in the presence of 5  g/ml brefeldin A. After stim-
ulation, cells were washed twice with PBS, pH 7.2, fixed 15 min
with formaldehyde (2% in PBS, pH 7.2), washed twice with
0.5% BSA in PBS, pH 7.2, permeabilized with PBS, pH 7.2,
containing 0.5% BSA and 0.5% saponin, and then incubated for
15 min at room temperature with the specific mAb. Cells were
then washed and analyzed on a BD-LSR cytofluorimeter using
the CELLQuest™ software (Becton Dickinson). The area of pos-
itivity was determined using an isotype-matched mAb, a total of
104 events for each sample were acquired.
Proliferation Assays. To assess the proliferative response of
human CD4 CD25  and CD4 CD25  thymocytes, allogeneic
PBMNCs, depleted of T cells by the use of anti-CD3 MACS®
microbeads were used. 105 irradiated (6,000 rad) T cell–depleted
PBMNCs were cultured with 5   104 purified CD4 CD25  or
CD4 CD25  thymocytes. On day 5, after 8-h pulsing with 0.5
 Ci  3[H]TdR/well (Amersham Pharmacia Biotech), cultures
were harvested and radionuclide uptake measured by scintillation
counting.
For the assessment of suppressive properties, 5   104
CD4 CD25  thymocytes were cultured with 105 irradiated T
cell–depleted allogeneic PBMCs in the presence of different
numbers of CD4 CD25  autologous thymocytes. In some ex-
periments, 10  g/ml anti–TGF- 1, 10  g/ml anti–CTLA-4,
anti-TGF- 1 plus anti-CTLA-4, or isotype control (IgG1 
IgG2a 10  g/ml each) mAbs were added to the cultures. On day
5, after 8-h pulsing with 0.5  Ci  3[H]TdR/well (Amersham
Pharmacia Biotech), cultures were harvested and radionuclide
uptake measured by scintillation counting. In other experiments,
the ability of CD4 CD25  cells to inhibit the proliferation of
CFSE-labeled CD4 CD25  thymocytes in MLC to irradiated al-
logenic human adult PB non-T cells was evaluated at different
time intervals by flow cytometry. In the same experiments, the
expression of CD25 and CD69 in both the CFSE CD3  regula-
tory population and CFSE CD3  target population was also
evaluated. In parallel, MLCs were performed in presence or ab-
sence of 10 IU/ml IL-2 or 10 ng/ml IL-15 and thymidine incor-
poration was evaluated on day 5.
Transwell Experiments. Transwell experiments were per-
formed in 24-well transwell plates (0.22  m pore size; Costar).
5   105 CD4 CD25  thymocytes were stimulated with 106 irradi-
ated T cell–depleted allogeneic PBMNCs in the bottom cham-
ber, in the absence or presence of 5   105 CD4 CD25  thy-
mocytes placed in the same or in the top chamber. On day 5,
after 8-h pulsing with 0.5  Ci 3[H]TdR/well (Amersham Phar-
macia Biotech), the cells of the lower chambers were harvested
and radionuclide uptake was measured by scintillation counting.
Statistical Analysis. Statistical analysis was performed using the
Student’s t test.
Results
Functional Properties of CD4 CD25  Human Thy-
mocytes. CD4 CD25  T cells were purified from six
postnatal human thymuses by negative selection of CD4 ,
followed by positive selection of CD25  cells. The purified
population consistently contained  98% CD4 CD25 
thymocytes, meanly representing 7% ( 2) of the entire SP
CD4 CD3  thymocyte population (Fig. 1). The ability of
purified CD4 CD25  and CD4 CD25   thymocytes to
Figure 1. Identification and purification of CD4 CD25  human thy-
mocytes. Freshly isolated human thymocytes were assessed for the ex-
pression of CD3, CD4, CD8, and CD25 by flow cytometry. After
MACS® sorting, purified CD4 CD25  thymocytes were assessed for
CD8 and CD25 expression. One representative experiment is shown.382 CD4 CD25  Regulatory Human Thymocytes
proliferate in MLC to irradiated allogeneic human adult PB
non-T cells was then assessed. As shown in Fig. 2 A,
CD4 CD25  thymocytes virtually did not proliferate in
response to allogeneic stimulation, whereas under the same
experimental conditions, the CD4 CD25  thymocyte
fraction showed strong proliferation. The suppressive activ-
ity of the CD4 CD25  thymocyte population was then
evaluated by adding increasing numbers of CD4 CD25 
cells to the autologous CD4 CD25  counterpart, stimu-
lated with irradiated allogeneic non-T cells. As shown in
Fig. 2 B, CD4 CD25  thymocytes inhibited in a dose-
dependent fashion the MLC response obtained with the
CD4 CD25  thymocyte population. In additional experi-
ments, in which CD4 CD25  thymocytes were isolated
paralleled by either the MACS® system or FACS® sorting,
quite comparable results were obtained (unpublished data).
Markers and Localization of CD4 CD25  Regulatory Thy-
mocytes. Having established that purified CD4 CD25 
human thymocytes showed the classic in vitro functional
activities described for murine Treg cells, i.e., poor or no
proliferation, as well as suppressive activity, the expression
on these cells of some markers was analyzed. Virtually all
CD4 CD25  thymocytes constitutively expressed cyto-
plasmic CTLA-4, as well as surface TNFR2 (Fig. 3 A).
Moreover, they expressed CCR8, whereas CCR4 was de-
tectable on a small proportion of these cells and was also
Figure 2. CD4 CD25  human thymocytes do not proliferate in MLC and suppress the proliferation in MLC of CD4 CD25  thymocytes. (A) Prolif-
erative response of purified CD4 CD25  (white columns) and CD4 CD25  (black columns) human thymocytes to allogeneic stimulation. Mean values
( SD) obtained in six separate experiments are reported. (B) Suppression by CD4 CD25  thymocytes of the proliferative response of autologous
CD4 CD25  thymocytes to allogeneic T cell–depleted PBMNCs. Mean values ( SD) obtained in six separate experiments are reported.
Figure 3. All CD4 CD25   human thymocytes
constitutively express cytoplasmic CTLA-4 and surface
TNFR2, CCR8 and exhibit chemotactic response to
CCL1/I-309. (A) Freshly purified CD4 CD25  and
CD4 CD25  thymocytes were assessed for the ex-
pression of cytoplasmic CTLA-4 and surface TNFR2
by flow cytometry. The cytofluorimetric picture ob-
tained with IgG2a isotype control is also depicted.
One representative of four experiments is shown. (B)
Expression of CCR4 and CCR8 on the surface of
CD4 CD25  or CD4 CD25  thymocytes. The cyto-
fluorimetric picture obtained with IgG1 and rabbit IgG isotype controls is also depicted. One representative
of four experiments is shown. (C) Chemotactic response of CD4 CD25  and CD4 CD25  thymocytes to
CCL1/I-309 or CCL22/MDC. Cell migration of CD4 CD25  (white columns) or CD4 CD25  (black
columns) thymocytes was evaluated by counting migrated cells with BD-LSR cytometer. Values are ex-
pressed as percentage increase of cells migrated in response to CCL1/I-309 or CCL22/MDC versus cells
migrated in the presence of medium alone (32.3   1.7   103). Mean values ( SD) obtained in three sepa-
rate experiments are reported.383 Annunziato et al.
present on a number of CD4 CD25  thymocytes (Fig. 3
B). CD4 CD25  and CD4 CD25  thymocyte popula-
tions were then assessed for their ability to respond to the
chemoattractant activity of CCR8 and CCR4 ligands,
CCL1/I-309 and CCL22/MDC, respectively. CCL22/
MDC induced migration of both CD4 CD25   and
CD4 CD25  thymocyte populations, whereas CCL1/I-
309 induced migration of the latter alone (Fig. 3 C). By us-
ing immunohistochemical staining with anti-CD25 mAb,
CD4 CD25  thymocytes were mainly detected in the fi-
brous septa with prevalent perivascular localization (Fig. 4,
A and B), lower numbers of these cells also being present in
the medullary areas (unpublished data). Immunostaining
with anti-CCR8 Ab confirmed such a localization (Fig. 4,
C–E). The nature and the localization of thymic cells pro-
ducing the CCR8 ligand, CCL1/I-309, was also analyzed.
Most CCL1/I-309–producing cells were detected in the fi-
brous septa, and some of them also in the medulla (Fig. 4,
F–L). Part of CCL1/I-309–producing cells costained for
cytokeratin (Fig. 4 F), revealing their nature of epithelial
cells, whereas a proportion of them costained for CD68
(Fig. 4 G), but never for CD3 (Fig. 4 H), CD83 (Fig. 4 I)
or CD11c (unpublished data), thus suggesting they were
macrophages. Of note, virtually all CCL1/I-309–produc-
ing cells in the septa were epithelial cells, whereas CCL1/I-
309–producing cells present in the medullary areas were ei-
ther epithelial cells or macrophages.
The Suppressive Activity of CD4 CD25  Regulatory Thy-
mocytes Is Contact-dependent and Mediated by CTLA-4 and
mTGF- 1. After 6 d of stimulation with insolubilized
anti-CD3 plus soluble anti-CD28 mAbs of CFSE-labeled
CD4 CD25  and CD4 CD25  thymocytes, cells were
further stimulated with PMA plus ionomycin. In agree-
ment with the results obtained by measuring 3[H]TdR in-
corporation, the CD4 CD25  cells showed strongly re-
duced proliferation, as assessed by CFSE content (Fig. 5 A).
Moreover, the same cells did not produce IL-2, IL-4, IL-5,
IL-13, or IFN- , and only a very few of them produced
IL-10, as assessed by flow cytometry at single cell level (Fig.
5 A). However, stimulation with insolubilized anti-CD3
plus soluble anti-CD28 mAbs, induced virtually all CD4 
CD25  thymocytes to express CTLA-4 on their surface
and about a half of them also mTGF- 1 (Fig. 5 B). The
latter finding is of interest, since mTGF- 1 has recently
been suggested to play a role in the suppressive activity of
murine CD4 CD25  Treg cells (19). To provide direct
evidence that mTGF- 1 was also involved in the suppres-
sive activity of CD4 CD25  human thymocytes, we first
assessed the effect of purified CD4 CD25  thymocytes on
the response of CD4 CD25  T cells in MLC by using
transwell chambers, in which the proliferative response of
CD4 CD25  T cells to irradiated allogeneic non-T cells
placed in the lower chamber was evaluated in absence
(top chamber) or in presence (bottom chamber) of CD4 
CD25  T cells. As shown in Fig. 6 A, the proliferative re-
sponse of CD4 CD25  T cells was strongly inhibited by
CD4 CD25  T cells, but only when they were present in
the same chamber, indicating that the suppressive activity
of these cells was mediated by cell-to-cell contact and not
via the release of soluble factors.
The nature of molecule(s) present on the surface of
CD4 CD25  thymocytes that were responsible for their
suppressive activity was then investigated. To do this, dif-
Figure 4. Localization of CD4 CD25  and of CCL1/I-309–express-
ing cells in human thymus. (A) Thymic sections stained with anti-CD25
mAb (red color) and counterstained with Gill’s Hematoxylin (original
magnification:   250). (B) Double staining of the same thymus with
anti-CD4 (bluish gray) and anti-CD25 (red color) mAb; no counterstain
was applied (original magnification:  400). (C) Double staining with
anti-CD25 mAb (bluish gray) and anti-CCR8 polyclonal Ab (red color);
no counterstain was applied (original magnification:  400). (D) Double
staining with anti-CCR8 polyclonal Ab (red color) and an isotype-
matched mAb with irrelevant specificity (bluish gray); no counterstain
was applied (original magnification:  400). (E) Absence of staining in the
same thymus using a rabbit polyclonal Ab with irrelevant specificity (orig-
inal magnification:  400). (F) Double staining with anti–CCL1/I-309
(red) and anti-CK (bluish gray) Abs. Arrows indicate cells showing dou-
ble staining for CCL1/I-309 and CK; no counterstain was applied (origi-
nal magnification:  400). (G) Double staining with anti-CCL1/I-309
(red) and anti-CD68 (bluish gray). Arrows indicate cells showing double
staining for CCL1/I-309 and CD68; no counterstain was applied (origi-
nal magnification:  400). (H) Double staining with anti–CCL1/I-309
(red) and anti-CD3 (bluish gray); no counterstain was applied (original
magnification:  400). (I) Double staining with anti–CCL1/I-309 poly-
clonal Ab (red color) and an isotype-matched mAb with irrelevant speci-
ficity (bluish gray); no counterstain was applied (original magnification:
 400). (L) Double staining with anti–CCL1/I-309 (red) and anti-CD83
(bluish gray); no counterstain was applied (original magnification:  400).
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ferent numbers of purified CD4 CD25  thymocytes were
added to cultures of CD4 CD25  T cells stimulated in
MLC in absence or presence of neutralizing anti–CTLA-4,
anti–TGF- 1, anti–CTLA-4 plus anti–TGF- 1, or isotype
control, mAbs. The results of these experiments are sum-
marized in Fig. 6 B. The addition of isotype control mAbs
did not exert any effect on the inhibitory activity of
CD4 CD25  thymocytes on the proliferative response of
CD4 CD25  T cells. By contrast, the addition of either
anti–CTLA-4 or anti–TGF- 1 mAb partially, but consis-
tently, reduced the inhibitory activity of CD4 CD25  thy-
mocytes, and such a suppressive activity was completely
abolished by the contemporaneous addition of the two
mAbs. Of note, similar effects as those induced by the anti–
TGF- 1 mAb were observed by adding in culture an anti–
TGF- 1R mAb (unpublished data).
CTLA-4 and TGF- 1 Exert Their Suppressive Activity by
Inhibiting the Expression of IL-2R  -Chain and the Re-
sponsiveness of Target T Cells to IL-2. The mechanism by
which CTLA-4 and/or mTGF- 1 exerted their inhibitory
Figure 5. Activated CD4 CD25  human thymocytes do not pro-
duce cytokines, but express mTGF- 1 and CTLA-4. CFSE-labeled
CD4 CD25  or CD4 CD25  thymocytes were incubated with insolu-
bilized anti-CD3 mAb plus soluble anti-CD28 mAb. (A) On day 6, cells
were stimulated with PMA plus ionomycin and cytokine synthesis at single
cell level was analyzed on a BD-LSR cytofluorimeter using CELLQuest™
software (Becton Dickinson). (B) Before PMA plus ionomycin stimula-
tion, CD4 CD25  and CD4 CD25  thymocytes were assessed for the
expression of surface CTLA-4 and mTGF-31, by flow cytometry.
Figure 6. Cell contact–dependent suppressive activity of CD4 CD25  human thymocytes is abrogated by the combined action of anti–CTLA-4 and
anti-TGF 1 mAbs. (A) CD4 CD25  thymocytes were stimulated with irradiated T cell–depleted allogeneic PBMNCs in the lower chamber of a transwell
plate in the absence or presence of CD4 CD25  thymocytes, placed in the same or in the top chamber. On day 5, cells present in the bottom chamber
were harvested and their proliferation assessed by measuring 3[H]TdR uptake. (B) CD4 CD25  thymocytes were stimulated with allogeneic irradiated T
cell–depleted PBMNCs in the presence of different numbers of autologous purified CD4 CD25  thymocytes without (black columns) or with isotype
control (IgG1 IgG2a) (gray columns), anti-CTLA-4 (hatched columns), or anti–TGF- 1 mAb (dotted columns), or mixtures of them (white columns).
Cell proliferation was measured by assessment of 3[H]TdR uptake. Mean values ( SD) obtained in four separate experiments are reported.385 Annunziato et al.
activity on the proliferation of CD4 CD25  thymocytes
was finally investigated. To this end, CD4 CD25  thy-
mocytes stimulated in MLC were cultured alone or
together with autologous CD4 CD25  thymocytes, in pres-
ence of neutralizing anti–CTLA-4, anti–TGF- 1, anti–
CTLA-4 plus anti–TGF- 1, or isotype control, mAbs. The
proliferative response of CD4 CD25  thymocytes, as well
as their ability to express CD25 under this different experi-
mental conditions, was then assessed by flow cytometry. As
expected, CD4 CD25  thymocytes stimulated in absence
of CD4 CD25  cells showed strong proliferation, and
proliferating cells expressed high CD25 levels, whereas
those stimulated in presence of CD4 CD25  cells did nei-
ther proliferate, nor expressed CD25. However, CD25 ex-
pression by these cells was restored by the addition of anti–
CTLA-4, anti–TGF- 1, and even more by anti–CTLA-4
plus anti-TGF- 1, mAbs, whereas the addition of isotype
control mAbs had no effect. By contrast, the expression of
another T cell activation marker, such as CD69, was not al-
tered (Fig. 7, A and B). These data suggest that both
CTLA-4 and mTGF- 1 contribute to suppress the prolif-
eration of stimulated CD4 CD25  thymocytes by inhibit-
ing the expression of IL-2R  -chain, thus rendering these
cells unresponsive to IL-2.
To support this possibility, IL-2 or IL-15 were added to
cultures of CD4 CD25  thymocytes, stimulated in MLC
in absence or presence of autologous CD4 CD25  cells,
and the degree of radionuclide incorporation was assessed.
As shown in Fig. 7 C, the suppressive activity exerted by
CD4 CD25  thymocytes on the proliferation of the
CD4 CD25  counterpart, was not significantly affected by
the addition in culture of IL-2, whereas IL-15 completely
restored the proliferative response of these cells.
Discussion
CD4 CD25  Treg cells are essential for the mainte-
nance of self-tolerance in mice (1–5). Similar cells have also
been described in humans (6–13), but the phenotypic and
functional features of human CD4 CD25  Treg cells, as
well as their mechanism of action, are controversial. This is
due, at least in part, to the fact that most studies were per-
formed by using purified PB CD4 CD25  T cells, which
represent a heterogenous population, containing activated
effector, in addition to regulatory, T cells (14). For exam-
ple, it was reported that PB CD4 CD25  cells do not pro-
duce any cytokine (7, 14), or secrete IL-2 or IL-4, but low
levels of IFN-  and higher levels of IL-10 and TGF-  (9),
or IL-10 alone (11), or higher levels of IL-4, and similar
amounts of IL-10, as CD4 CD25  cells (13). The possible
phenotypic markers of human CD4 CD25  human PB
Treg cells are also partially known. These cells express
CD45RO and HLA-DR (8, 9, 11, 14), but these mole-
cules are also present on the surface of effector T cells.
Most studies reported CTLA-4 upregulation in these cells
(7–11). The CD62L has also been found to be expressed
(8), whereas CD40L is downregulated (8) or is expressed at
the same levels than in CD4 CD25  T cells (11). In a re-
cent report, it has been found that CD4 CD25  PB Treg
cells express the chemokine receptors CCR4 and CCR8
and are chemoattracted by the respective ligands, CCL17/
TARC, CCL22/MDC, and CCL1/I-309 (12). The mech-
anism of action of CD4 CD25  PB Treg cells also remains
to be determined. Several studies agree that the suppressive
activity of these cells requires cell-to-cell contact and is cy-
tokine independent (7, 8, 11). However, although a possi-
ble role for CTLA-4 and PDL1 in T cell–T cell regulation
has recently been suggested (14), the surface molecules in-
volved in the interactions responsible for suppression have
not yet been clearly defined.
Figure 7. CTLA-4 and TGF- 1–mediated suppression is due to the
inhibition of IL-2R  -chain expression and is overcome by IL-15. (A)
CFSE-labeled CD4 CD25  thymocytes were stimulated with irradiated
allogeneic PB non-T cells in absence or presence of autologous
CD4 CD25  thymocytes with anti–CTLA-4, anti–TGF- 1, anti–
CTLA-4 plus anti–TGF- 1 or isotype-matched (IgG1 plus IgG2a) mAbs,
and assessed by flow cytometry for proliferation and surface CD25 ex-
pression. One representative of three separate experiments is shown. (B)
CD25 (left) and CD69 (right) expression by CD4 CD25  thymocytes
cultured under the experimental conditions mentioned in (A).
CD4 CD25  thymocytes without mAb added (black columns), or con-
taining isotype control (gray columns), anti–TGF- 1 (dotted columns),
anti–CTLA-4 (hatched columns), or anti–CTLA-4 plus anti–TGF- 1
(white columns) mAbs. Columns represent mean values ( SD) found in
three separate experiments. (C) Effect of the addition of exogenous IL-2
or IL-15 on the proliferative response of CD4 CD25  thymocytes stimu-
lated with irradiated allogeneic non-T cells in absence or presence of
CD4 CD25  autologous thymocytes. Columns represent mean values
( SD) obtained in three separate experiments.386 CD4 CD25  Regulatory Human Thymocytes
In this study, we attempted to better characterize the
phenotype of human CD4 CD25  Treg cells, as well the
mechanisms involved in their suppressive activity by assess-
ing the CD4 CD25  population present in postnatal hu-
man thymuses. Indeed, we hypothesized that CD4 
CD25  thymocytes may represent a less heterogenous
population than PB CD4 CD25  T cells, thus avoiding
possible interferences due to contaminating CD4 CD25 
T cells with different or even opposite functions. So far,
only one study dealing with CD4 CD25  human thy-
mocytes has been performed (13), but no information
other than the suppressive activity of these cells and their
inability to produce cytokines was reported (13). The re-
sults of the present study allow to draw a number of con-
clusions on the phenotype, localization, and some func-
tional features of CD4 CD25  cells, as well as on the
mechanisms involved in their suppressive activity. First, in
agreement with the results already reported by Stephens et
al. (13), CD4 CD25  human thymocytes were unable to
proliferate and suppressed in a dose-dependent fashion the
proliferation of other CD4  T cells in vitro. Second, they
were characterized by the selective constitutive expression
of CD25hi, cytoplasmic CTLA-4, surface TNFR2, and
CCR8, whereas their surface CCR4 expression was lim-
ited and not selective. Third, these cells were mainly ob-
served in the context of the fibrous septa of the thymus
with prevalent perivascular localization, and responded to
the chemoattractant activity of CCL1/I-309. Characteriza-
tion of CCL1/I-309–producing cells by double immuno-
staining revealed that epithelial cells were the source of this
chemokine in the fibrous septa, whereas small numbers of
epithelial cells and macrophages producing CCL1/I-309
were found in the medullary areas. Taken together, these
data support the view that CCL1/I-309-CCR8 interaction
is probably essential for the migration of this subset within
the thymus or from the thymus to the periphery.
In addition, after polyclonal stimulation with PMA plus
ionomycin, CD4 CD25  human thymocytes did not pro-
duce IL-2, IL-4, IL-5, IL-13, IFN- , and only a very few
of them produced IL-10. However, stimulation with anti-
CD3 plus anti-CD28 mAbs induced virtually all CD4 
CD25  human thymocytes to express on their surface
membrane CTLA-4, and  50% of them also TGF- 1.
Since the regulatory activity of CD4 CD25  human thy-
mocytes was found to be clearly dependent by cell-to-cell
contact, we asked whether the neutralization of molecules
selectively expressed by these cells could also inhibit their
suppressive activity. While the addition in culture of iso-
type control mAbs had no effect, blocking of either
CTLA-4, TGF- 1, or TGF- 1R, partially, but consis-
tently, inhibited the suppressive activity of CD4 CD25 
human thymocytes. More importantly, such a suppressive
activity was completely abolished by the contemporaneous
addition of anti–CTLA-4 and anti–TGF- 1 mAbs. These
findings suggest that both CTLA-4 and mTGF- 1 are in-
volved in the suppressive activity of these cells.
The results reported in this study are not fully consistent
with those of studies performed so far by using PB
CD4 CD25  T cells, which failed to demonstrate reversal
of suppression with anti–CTLA-4 or anti–TGF-  Abs (8, 9,
11, 13, 14). This discrepancy may be due to either the het-
erogeneity of PB in comparison with thymus-derived
CD4 CD25  T cells, or to the different assays used to assess
the suppressive activity. However, the role of CTLA-4 in
the regulatory activity of murine CD4 CD25  T cells has
been clearly demonstrated in vivo (5, 6). More importantly,
in a recent study it was shown that the suppressive activity
of CD4 CD25  murine T cells was abolished by the neu-
tralization of TGF-  and that stimulated CD4 CD25  T
cells expressed high and persistent levels of TGF- 1 on
their cell surface (19). Since CTLA-4 engagement has been
found to enhance the secretion of TGF-  (20), it is reason-
able to explain why in this study a complete inhibition of
the suppressive activity exerted by activated CD4 CD25 
human thymocytes could be achieved only when both
CTLA-4 and TGF- 1 were neutralized. Considering that
complete anti–CTLA-4 mAb instead of its Fab fragment
was used, the possibility of signaling instead of blocking ef-
fects cannot be excluded. However, based on the fact that
similar effects were obtained by using either anti–CTLA-4,
anti–TGF- 1, or anti–TGF- 1R mAbs, and even more,
when anti–CTLA-4 and anti–TGF- 1 mAbs were com-
bined, this possibility appears to be unlikely.
The results of this study also provide insights into the
mechanisms by which TGF- 1 expressed on the surface of
CD4 CD25  thymocytes is able to suppress the prolifera-
tive response of stimulated CD4 CD25  cells. Indeed, we
found that under these conditions, the latter cells could ex-
press the T cell activation marker CD69, but not the IL-
2R  -chain and, therefore, became unresponsive to IL-2.
This possibility was supported by the observation that the
inability of target T cells to proliferate was not affected by
the addition of exogenous IL-2, but it was overcome by
the addition of IL-15, a T cell stimulatory cytokine that
does not use the high affinity IL-2R (21). These findings
are consistent with the results of a recent study, showing
suppression of IL-2–induced human T cell proliferation
and phosphorylation of signal transducer and activator of
transcription (STAT)-3 and STAT-5 by TGF-  (22). The
suppression of intracellular signaling and proliferation me-
diated by TGF-  could be completely overcome by treat-
ing T cells with IL-15 (22). Thus, the results of the experi-
ments here reported not only allow to better characterize
some phenotypic and functional aspects of human CD4 
CD25  Treg cells, but also provide new insights into their
mechanism of action.
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